Overview
CJC-1295 and ipamorelin have each been studied for growth-hormone responses. The cited human studies tested them separately; they do not demonstrate that taking the pair improves sleep, muscle gain, fat loss, or injury recovery.[1][2] The evidence therefore needs to be read at the level of the actual intervention and measured outcome. This guide separates findings about the individual ingredients from findings about the complete combination, and keeps unresolved questions about formulation, benefit, and safety visible.
Ingredients
- CJC-1295Distinguish long-acting CJC-1295 from products labeled “no DAC.”
- IpamorelinHuman pharmacology is different from a recovery or sleep trial.
The CJC-1295 trial investigated a long-acting molecule. Its prolonged hormone effects cannot simply be assigned to a differently specified product sold as “CJC-1295 no DAC.”[1] Confirm the chemical identity and formulation before matching a product to a paper. A similar label does not prove the same exposure, duration of action, or safety profile. Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.
Why combine them?
No. A rationale for combining agents still needs a controlled test of the pair. The selected single-agent studies cannot show whether adding ipamorelin produces a worthwhile benefit, adds risk, or changes neither for a particular outcome.[1][2] A meaningful trial would assess the combination against relevant comparators and report clinical outcomes alongside adverse events, rather than relying on hormone changes alone.
Combination benefits
Two short randomized, placebo-controlled trials found that long-acting CJC-1295 increased GH and IGF-1 in healthy adults. The principal outcomes were hormone concentrations and pharmacokinetics.[1] An ipamorelin infusion study in healthy men characterized the drug’s disposition and GH response. It did not test the CJC-1295 combination or a consumer recovery regimen.[2] A biomarker change is a finding, but it is not interchangeable with a patient benefit. The next question is whether the claimed outcome was measured and improved.
Safety & interactions
FDA flags immune-reaction concerns for both substances and reports serious events in the available CJC-1295 and intravenous-ipamorelin literature; the route and clinical context matter.[3] The short studies do not establish long-term combination safety. A lack of serious reactions in a small trial is not a guarantee for a different product or regimen.[1][2] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.
Forms & dosing
These single-agent experiments do not establish a combined regimen for sleep, body composition, or recovery.[1][2] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use. The separate studies therefore cannot establish an appropriate ratio between the two ingredients.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Human researchIndirect single-agent human studies.[1][2] Separate hormone-response studies cannot establish the combination’s clinical benefit.[1][2] Main limitation: The intervention and endpoints differ from the stack claims.[1][2] | ||
| Context sourcesRegulatory safety assessment.[3] Available safety information does not validate long-term use of the combination.[3] Main limitation: Regulatory concerns cannot be converted into a reliable event rate for the pair.[3] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.
Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth
Probing for peptidic drugs (2–10 kDa) in doping control blood samples
Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
Growth Hormone (GH) Hypersecretion and GH Receptor Resistance in Streptozotocin Diabetic Mice in Response to a GH Secretagogue
FAQs
Does CJC-1295 with ipamorelin improve sleep?
The cited studies primarily assess hormone responses, not sleep improvement from the pair. They cannot establish that claim.[1][2] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.
Does a higher IGF-1 level prove muscle gain?
No. Hormone concentration is a different endpoint from muscle size, strength, or physical function. Those outcomes need their own evidence. The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.
Can I use CJC-1295 trial results for a “no DAC” blend?
Only after establishing that the actual molecule and formulation match. The long-acting CJC-1295 study cannot validate a product solely because the label uses a similar name.[1] Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for CJC-1295 + ipamorelin.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
3 sources
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults (2006)Primary research · Human randomized trialsReview status · PendingSave study
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999)Primary research · Human pharmacology studyReview status · PendingSave study
- FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Accessed 2026-10-04)Regulatory assessmentSave study
